Anticoagulants Market Report 2025

This Anticoagulants market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The anticoagulants market size has grown rapidly in recent years. It will grow from $49.33 billion in 2024 to $54.39 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to aging population, increased prevalence of cardiovascular diseases, rising awareness aboutThe importance of anticoagulantTherapy, expansion of indications for anticoagulant use, increased incidence of venous thromboembolism (VTE) and atrial fibrillation.

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $87.76 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expansion of indications for novel anticoagulant drugs, rising healthcare expenditure, emergence of novel oral anticoagulants (NOACs) as primary treatment options, financial support offered by central authorities to revamp healthcare facilities, expansion of the healthcare infrastructure. Major trends in the forecast period include advancements in medical technologies and diagnostic methods, integration of artificial intelligence and data analytics in anticoagulant therapy, growing emphasis on patient education and adherence programs, development of reversal agents.

The rising incidence of cardiovascular diseases is a significant factor propelling the growth of the anticoagulants market in the coming years. Cardiovascular diseases (CVDs) encompass a range of heart and blood vessel disorders and are the leading cause of death globally, with low- and middle-income countries accounting for three-quarters of these fatalities. Direct oral anticoagulants, a form of anticoagulation pharmacotherapy, are utilized to reduce thrombosis in various cardiovascular conditions. For example, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government agency, revealed that there were 702,880 deaths from heart disease in the United States in 2022, with 371,506 of those due to coronary artery disease. Furthermore, approximately 805,000 individuals in the country suffer a heart attack each year. Thus, the growing prevalence of cardiovascular diseases is driving the expansion of the anticoagulants market.

The growing number of hospitals is anticipated to drive the expansion of the anticoagulants market in the future. Hospitals are healthcare facilities that provide medical treatment, care, and support to individuals dealing with various illnesses, injuries, or medical conditions. Anticoagulants are utilized in hospitals to prevent blood clots, treat thromboembolic disorders, manage heart conditions, prevent recurrent strokes, and reduce the risk of postoperative complications. For example, in January 2024, a report from the American Hospital Association (AHA), a US-based healthcare trade organization, indicated that in the United States, federal government hospitals increased from 206 to 207 between fiscal years 2021 and 2022, while hospitals in the "other" category grew from 107 to 125. Consequently, the rising number of hospitals is fueling the growth of the anticoagulants market.

Major companies in the anticoagulants market are concentrating on developing innovative solutions, such as factor Xa inhibitor tests, to address the rising demand for testing stemming from the increased use of direct oral anticoagulants for stroke prevention and other severe cardiovascular conditions. Factor Xa Inhibitor Tests are designed to assess the effectiveness and safety of anticoagulant medications that selectively inhibit factor Xa, thereby preventing blood clot formation in various medical scenarios. For example, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, introduced coagulation tests for apixaban, edoxaban, and rivaroxaban. These new coagulation tests for Factor Xa inhibitors employ Roche's innovative reagent cassette concept, which ensures high-quality results and efficient sample processing while providing standardization and automation for improved laboratory workflows. These tests are crucial as they aid clinical decision-making for patients using direct oral anticoagulants for stroke prevention, catering to the growing global demand for effective diagnostics in managing serious conditions like coronary artery disease and peripheral arterial disease.

Prominent entities within the anticoagulants market are directing their focus towards innovative products, such as the sodium citrate 4% anticoagulant solution, to bolster their market revenues. This medical solution consists of a liquid form containing 4% sodium citrate, serving the purpose of preventing blood clotting. For instance, in August 2023, Fresenius Kabi AG, a Germany-based healthcare group specializing in pharmaceuticals and medical devices, introduced the sodium citrate 4% anticoagulant solution. When utilized in conjunction with apheresis equipment, this solution becomes vital for collecting and preserving blood and its components. The 250 mL container of sodium citrate 4% anticoagulant solution is meticulously crafted to adhere to Canada's stringent requirements for plasma donation. By binding calcium ions, sodium citrate effectively prevents the coagulation cascade, maintaining blood in a liquid state suitable for diagnostic testing and various medical procedures.

In August 2022, Pharmaniaga Berhad, a Malaysia-based pharmaceutical company, forged a partnership with Suzhou Ronnsi Pharma Co. Ltd. This strategic collaboration aims to address the escalating demand for therapies targeting non-communicable diseases, driven by an aging population, and specifically caters to the burgeoning market for halal medications. The partnership between Pharmaniaga Berhad and Suzhou Ronnsi Pharma Co. Ltd aims to facilitate commerce in pharmaceutical products, research and development initiatives, and ultimately, the production of a halal ovine anticoagulant product. Suzhou Ronnsi Pharma Co. Ltd, based in China, specializes in manufacturing anticoagulants and forms a crucial part of this collaboration aimed at meeting the growing demand for halal pharmaceuticals in the market.

Major companies operating in the anticoagulants market include GlaxoSmithKline plc, Leo Pharma A/S, Alexion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N. V., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi S. A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, CSL Behring, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, Zydus Cadila Healthcare Limited.

Anticoagulants, commonly known as blood thinners, are drugs used to prevent and treat blood clots in the heart and blood arteries. They work by slowing down the body's clotting process, reducing the risk of clot formation.

The main drug classes of anticoagulants include Factor Xa Inhibitor, Heparin & LMWH (Low Molecular Weight Heparin), Vitamin K Antagonist, and others. Factor Xa inhibitors specifically and reversibly block the function of clotting factor Xa, preventing clot formation. Anticoagulants can be administered orally or through injections, and they are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Anticoagulants are used in the treatment of conditions such as venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, among others. They are employed in various healthcare settings, including hospitals, home care, specialty centers, and others.

The anticoagulants market research report is one of a series of new reports that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with an anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the anticoagulants market in 2024. The regions covered in the anticoagulants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.